Market Place
Sourcing Support
Allogene Therapeutics Plans $175M Public Stock Offering
13 Apr 2026 //
GLOBENEWSWIRE
Allogene Therapeutics to Participate in Investor Conference
27 Aug 2025 //
GLOBENEWSWIRE
Allogene Therapeutics Reports Q4 and Full Year 2024 Results
13 Mar 2025 //
GLOBENEWSWIRE
Allogene Therapeutics Expands Partnership with Foresight Diagnost
25 Feb 2025 //
GLOBENEWSWIRE
Allogene Therapeutics To Report Q2 2024 Results
31 Jul 2024 //
GLOBENEWSWIRE
Allogene Activates Sites For ALPHA3 Trial Of Cema-cel In LBCL
01 Jul 2024 //
GLOBENEWSWIRE
Allogene Starts Phase 2 Trial For CAR T Product In Large B-Cell Lymphoma
20 Jun 2024 //
GLOBENEWSWIRE
Allogene Oncology Summit Featured: Cowen Participation Scheduled 2024
23 May 2024 //
GLOBENEWSWIRE
Allogene`s $110M offering
13 May 2024 //
PRESS RELEASE
Allogene Therapeutics Q1 2024 Financials, Business Update
13 May 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
13 May 2024 //
GLOBENEWSWIRE
Allogene To Report Q1 Results, Provide Business Update
06 May 2024 //
GLOBENEWSWIRE
Allogene Awarded CIRM Grant for Allogeneic CAR-T in Renal Cell Cancer
26 Apr 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Q2 Investor Conference Participation
09 Apr 2024 //
GLOBENEWSWIRE
Allogene Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Allogene to Report Fourth Quarter and Full Year 2023 Financial Results
05 Mar 2024 //
GLOBENEWSWIRE
Allogene Announces Participation in 44th Annual TD Cowen Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Allogene Therapeutics to Restate Previously Filed Financial Statements
16 Feb 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
16 Jan 2024 //
GLOBENEWSWIRE
Allogene makes `bold` pivot, stopping pivotal trials in pursuit of first-line CAR-T cures
06 Jan 2024 //
FIERCE BIOTECH
Allogene Announces Vision to Redefine Future of CAR T Led by ALPHA3
04 Jan 2024 //
GLOBENEWSWIRE
Allogene Therapeutics and Foresight Diagnostics Announce Partnership
04 Jan 2024 //
GLOBENEWSWIRE
Allogene to Host Conference Call Previewing its 2024 Platform Vision
03 Jan 2024 //
GLOBENEWSWIRE
Allogene Presents Safety Data of Proprietary Lymphodepletion Agent ALLO-647
09 Dec 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Participation in December Investor Conference
01 Dec 2023 //
GLOBENEWSWIRE
Allogene Presents Data on Allogeneic CAR T Product Targeting Claudin18.2
03 Nov 2023 //
GLOBENEWSWIRE
Allogene Presents Preclinical Data on Next Generation Cloak and Dagger
03 Nov 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting
02 Nov 2023 //
GLOBENEWSWIRE
Allogene Reports Third Quarter 2023 Financial Results and Business Update
02 Nov 2023 //
GLOBENEWSWIRE
Allogene to Report Third Quarter 2023 Financial Results on November 2, 2023
26 Oct 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
16 Oct 2023 //
GLOBENEWSWIRE
Allogene Announces Three Poster Presentations from its Next Generation AlloCAR T
27 Sep 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Participation in September Investor Conference
05 Sep 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Reports Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
Allogene to Report Second Quarter 2023 Financial Results on August 2, 2023
26 Jul 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral
15 Jun 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Departure of Chief Financial Officer
14 Jun 2023 //
GLOBENEWSWIRE
Allogene Announces Participation in Three Upcoming Investor Conferences
24 May 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Reports 1Q 2023 Financial Results and Business Update
03 May 2023 //
GLOBENEWSWIRE
Allogene Therapeutics to Report 1Q 2023 FYR on May 3, 2023
25 Apr 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
20 Apr 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316
17 Apr 2023 //
GLOBENEWSWIRE
Allogene Announces Participation in Four Upcoming Investor Conferences
13 Apr 2023 //
GLOBENEWSWIRE
Allogene Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
30 Mar 2023 //
GLOBENEWSWIRE
Allogene Announces Participation in Two Upcoming Investor Conferences
02 Mar 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study
01 Mar 2023 //
GLOBENEWSWIRE
Allogene Reports Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Allogene Therapeutics to Report Fourth Quarter Financial Results
21 Feb 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Presents Data on Dagger
01 Feb 2023 //
GLOBENEWSWIRE
Allogene Publishes Data Supporting DLL3 as a Potential AlloCAR T Target for SCLC
25 Jan 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Participation in Two Investor Conferences
17 Jan 2023 //
GLOBENEWSWIRE
Allogene to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
PRESS RELEASE
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive VP of R&D
03 Jan 2023 //
GLOBENEWSWIRE
Allogene Showcase Solid Tumor Advances Across its AlloCAR T Platform
29 Nov 2022 //
GLOBENEWSWIRE
Allogene takes the stage in NY to go deep on its off-the-shelf cell therapies
29 Nov 2022 //
ENDPTS
Allogene Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells
10 Nov 2022 //
GLOBENEWSWIRE
Allogene Therapeutics To Host Research & Development Showcase
09 Nov 2022 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Poster Presentation of Its Ph1 UNIVERSAL Trial
03 Nov 2022 //
GLOBENEWSWIRE
Allogene Therapeutics Reports Third Quarter 2022 Financial Results
02 Nov 2022 //
GLOBENEWSWIRE
Allogene Overland Biopharm completes Shanghai facility to manufacture CAR-T
02 Nov 2022 //
ENDPTS
